Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Advagene Biopharma Co., Ltd. (6709.TWO)

15.90
-0.30
(-1.85%)
At close: 2:16:53 PM GMT+8
Loading Chart for 6709.TWO
  • Previous Close 16.20
  • Open 15.85
  • Bid 15.85 x --
  • Ask 16.00 x --
  • Day's Range 15.75 - 16.25
  • 52 Week Range 15.75 - 30.00
  • Volume 116,500
  • Avg. Volume 191,615
  • Market Cap (intraday) 944.142M
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) --
  • EPS (TTM) -1.27
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. Its products in development include nasal spray influenza vaccine, allergy vaccines, and COVID-19 immunotherapy. The company is based in Taipei, Taiwan.

www.advagene.com.tw

12

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6709.TWO

View More

Performance Overview: 6709.TWO

Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6709.TWO
22.44%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
18.41%

1-Year Return

6709.TWO
5.36%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
3.18%

3-Year Return

6709.TWO
62.69%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
10.39%

5-Year Return

6709.TWO
10.38%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
82.32%

Compare To: 6709.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6709.TWO

View More

Valuation Measures

Annual
As of 4/21/2025
  • Market Cap

    973.83M

  • Enterprise Value

    778.08M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    4.42

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -23.29%

  • Return on Equity (ttm)

    -38.51%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -69.42M

  • Diluted EPS (ttm)

    -1.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    202.32M

  • Total Debt/Equity (mrq)

    2.64%

  • Levered Free Cash Flow (ttm)

    -46.06M

Research Analysis: 6709.TWO

View More

Company Insights: 6709.TWO

Research Reports: 6709.TWO

View More

People Also Watch